Tag : GLIOBLASTOMA

  • MEETING HIGHLIGHT
    Local real-world study interim analysis demonstrates promising results: TTFields therapy on quality-of-life for newly diagnosed glioblastoma patients

    With a rapidly deteriorating disease course, glioblastoma (GBM) is the most common and aggressive primary brain tumor with a typical 2-year and 5-year survival rate of 25% and 5-10%, respectively. Ever since the establishment of a standard-of-care treatment more than 15 years ago, comprising of surgical resection followed by adjuvant concurrent temozolomide chemo-radiotherapy (CCRT), little progress has been made. To address this unmet need, tumor-treating fields (TTFields) was introduced as a concurrent antimitotic treatment to CCRT and demonstrated a significant survival benefit among GBM patients worldwide as well as in Hong Kong. In the 27th Annual Scientific Meeting held by the Hong Kong Neurosurgical Society in December 2020, Dr. Peter Woo, Specialist in Neurosurgery, presented the interim analysis of a local study that demonstrated significant quality-of-life (QoL) and progression-free survival (PFS) benefits among newly-diagnosed GBM patients who received TTFields plus CCRT when compared to CCRT alone.

    doctor name

    Dr. Peter YM Woo

    Specialist in Neurosurgery